• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

游离和纳米包封的苯硝唑在急性感染中的作用:胆碱能途径和氧化还原状态的作用

Effects of Free and Nanoencapsulated Benznidazole in Acute Infection: Role of Cholinergic Pathway and Redox Status.

作者信息

da Silva Aniélen D, Fracasso Mateus, Bottari Nathieli B, Palma Taís V, Engelmann Ana M, Castro Milagros F V, Assmann Charles E, Mostardeiro Vitor, Reichert Karine P, Nauderer Jelson, da Veiga Marcelo L, da Rocha Maria Izabel U M, Milleti Luiz Claudio, das Neves Gabriella B, Gundel Samanta, Ourique Aline F, Monteiro Silvia G, Morsch Vera M, Chitolina Maria Rosa, Da Silva Aleksandro S

机构信息

Department of Biochemistry and Molecular Biology, Universidade Federal de Santa Maria, Santa Maria 97105-900, RS, Brazil.

Department of Microbiology and Parasitology, Universidade Federal de Pelotas, Pelotas 96015-560, Brazil.

出版信息

Pharmaceuticals (Basel). 2024 Oct 19;17(10):1397. doi: 10.3390/ph17101397.

DOI:10.3390/ph17101397
PMID:39459036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11510717/
Abstract

: The infection promotes an intense inflammatory process that affects several tissues. The cholinergic system may exert a regulatory immune response and control the inflammatory process. This study aimed to evaluate the comparative effect of free and nanoencapsulated benznidazole in acute infection to assess hematological, biochemical, and oxidative status triggered by the cholinergic system. : For this, fifty female Swiss mice were distributed in eight groups, i.e., uninfected and infected animals under four treatment protocols: untreated (control-CT); vehicle treatment (Eudragit L 100-EL-100); benznidazole treatment (BNZ); and nanoencapsulated benznidazole treatment (NBNZ). After eight treatment days, the animals were euthanized for sample collection. : The peak of parasitemia was at day 7 p.i., and the BNZ and NBNZ controlled and reduced the parasite rate but showed no efficacy in terms of total elimination of parasites analyzed by RT-PCR in both infected groups. The infection promotes significant anemia, leukopenia, and thrombocytopenia, which the BNZ improves. There was an increase in AChE activity during infection, leading to a pro-inflammatory response and an increase in M1 and M2 mACh receptors in the BNZ group, showing that the treatment interacted with the cholinergic pathway. In addition, a pro-oxidative response was characterized in the infection and mainly in the infected BNZ and NBNZ groups. The histopathological analysis showed significative splenomegaly and inflammatory infiltrate in the heart, liver, and spleen. : The administration of the BNZ or NBNZ reverses hematological, hepatic, and renal alterations through cholinergic signaling and stimulates a pro-inflammatory response during acute infection.

摘要

该感染会引发影响多个组织的强烈炎症过程。胆碱能系统可能发挥调节性免疫反应并控制炎症过程。本研究旨在评估游离型和纳米包封型苯硝唑在急性感染中的比较效果,以评估由胆碱能系统引发的血液学、生化和氧化状态。为此,将50只雌性瑞士小鼠分为八组,即未感染和感染动物,采用四种治疗方案:未治疗(对照-CT);载体治疗(Eudragit L 100-EL-100);苯硝唑治疗(BNZ);以及纳米包封型苯硝唑治疗(NBNZ)。治疗八天后,对动物实施安乐死以采集样本。寄生虫血症高峰出现在感染后第7天,BNZ和NBNZ控制并降低了寄生虫率,但在通过RT-PCR分析的两个感染组中,在完全消除寄生虫方面均未显示出效果。该感染会导致显著的贫血、白细胞减少和血小板减少,BNZ可改善这些情况。感染期间乙酰胆碱酯酶活性增加,导致促炎反应,且BNZ组中M1和M2毒蕈碱型乙酰胆碱受体增加,表明该治疗与胆碱能途径相互作用。此外,在感染中以及主要在感染的BNZ和NBNZ组中表现出促氧化反应。组织病理学分析显示心脏、肝脏和脾脏有明显的脾肿大和炎性浸润。BNZ或NBNZ的给药通过胆碱能信号逆转血液学、肝脏和肾脏改变,并在急性感染期间刺激促炎反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/f55330168366/pharmaceuticals-17-01397-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/3bfc20397f2d/pharmaceuticals-17-01397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/3c3cde634523/pharmaceuticals-17-01397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/ea182333157a/pharmaceuticals-17-01397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/f86109f54561/pharmaceuticals-17-01397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/c0c9c9207b1a/pharmaceuticals-17-01397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/e2108d55b494/pharmaceuticals-17-01397-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/4498147e6e7d/pharmaceuticals-17-01397-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/d0cad4a52b6e/pharmaceuticals-17-01397-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/967b7d8f9294/pharmaceuticals-17-01397-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/646b61bea973/pharmaceuticals-17-01397-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/a25f7afa03c7/pharmaceuticals-17-01397-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/9f4a73a223b6/pharmaceuticals-17-01397-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/7c9f628ac717/pharmaceuticals-17-01397-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/f55330168366/pharmaceuticals-17-01397-g014.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/3bfc20397f2d/pharmaceuticals-17-01397-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/3c3cde634523/pharmaceuticals-17-01397-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/ea182333157a/pharmaceuticals-17-01397-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/f86109f54561/pharmaceuticals-17-01397-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/c0c9c9207b1a/pharmaceuticals-17-01397-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/e2108d55b494/pharmaceuticals-17-01397-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/4498147e6e7d/pharmaceuticals-17-01397-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/d0cad4a52b6e/pharmaceuticals-17-01397-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/967b7d8f9294/pharmaceuticals-17-01397-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/646b61bea973/pharmaceuticals-17-01397-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/a25f7afa03c7/pharmaceuticals-17-01397-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/9f4a73a223b6/pharmaceuticals-17-01397-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/7c9f628ac717/pharmaceuticals-17-01397-g013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b702/11510717/f55330168366/pharmaceuticals-17-01397-g014.jpg

相似文献

1
Effects of Free and Nanoencapsulated Benznidazole in Acute Infection: Role of Cholinergic Pathway and Redox Status.游离和纳米包封的苯硝唑在急性感染中的作用:胆碱能途径和氧化还原状态的作用
Pharmaceuticals (Basel). 2024 Oct 19;17(10):1397. doi: 10.3390/ph17101397.
2
Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?克氏锥虫:纳米囊包苯硝唑的摄入是否能控制急性感染?
Exp Parasitol. 2023 Jun;249:108520. doi: 10.1016/j.exppara.2023.108520. Epub 2023 Mar 29.
3
Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease.阐明低剂量纳米制剂苯硝唑在急性实验性恰加斯病中的作用。
PLoS Negl Trop Dis. 2017 Dec 21;11(12):e0006119. doi: 10.1371/journal.pntd.0006119. eCollection 2017 Dec.
4
Promising Efficacy of Benznidazole Nanoparticles in Acute Trypanosoma cruzi Murine Model: In-Vitro and In-Vivo Studies.苯硝唑纳米颗粒在急性克氏锥虫小鼠模型中的潜在疗效:体外和体内研究
Am J Trop Med Hyg. 2016 Aug 3;95(2):388-93. doi: 10.4269/ajtmh.15-0889. Epub 2016 May 31.
5
Involvement of ectonucleotidases and purinergic receptor expression during acute Chagas disease in the cortex of mice treated with resveratrol and benznidazole.在使用白藜芦醇和苯并咪唑治疗的急性恰加斯病小鼠皮层中,细胞外核苷酸酶和嘌呤能受体表达的参与。
Purinergic Signal. 2021 Sep;17(3):493-502. doi: 10.1007/s11302-021-09803-9. Epub 2021 Jul 24.
6
The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection.疫苗相关化疗对慢性克氏锥虫感染小鼠模型肝脏健康的影响。
PLoS Negl Trop Dis. 2023 Nov 21;17(11):e0011519. doi: 10.1371/journal.pntd.0011519. eCollection 2023 Nov.
7
Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates.苯硝唑给药频率变化及剂量调整对感染克氏锥虫的小鼠、犬和非人灵长类动物的治疗作用。
Antimicrob Agents Chemother. 2023 May 17;67(5):e0013223. doi: 10.1128/aac.00132-23. Epub 2023 Apr 11.
8
Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by Trypanosoma cruzi in chronically-infected BALB/c mice.疫苗相关化疗结合低剂量苯硝唑和双价重组蛋白疫苗预防慢性感染 BALB/c 小鼠引起的克氏锥虫引起的心脏纤维化。
PLoS Negl Trop Dis. 2022 Sep 12;16(9):e0010258. doi: 10.1371/journal.pntd.0010258. eCollection 2022 Sep.
9
Nanocarrier-enhanced intracellular delivery of benznidazole for treatment of Trypanosoma cruzi infection.纳米载体增强贝诺喹在细胞内的递送用于治疗克氏锥虫感染。
JCI Insight. 2021 May 10;6(9):145523. doi: 10.1172/jci.insight.145523.
10
Effects of dehydroepiandrosterone-sulfate (DHEA-S) and benznidazole treatments during acute infection of two different Trypanosoma cruzi strains.脱氢表雄酮硫酸酯(DHEA-S)和苯并咪唑治疗在两种不同克氏锥虫株急性感染期间的效果。
Immunobiology. 2010 Dec;215(12):980-6. doi: 10.1016/j.imbio.2009.11.002. Epub 2010 Feb 16.

本文引用的文献

1
From Benznidazole to New Drugs: Nanotechnology Contribution in Chagas Disease.从苯唑达唑到新药:纳米技术在恰加斯病中的贡献。
Int J Mol Sci. 2023 Sep 7;24(18):13778. doi: 10.3390/ijms241813778.
2
Trypanosoma cruzi: Does the intake of nanoencapsulated benznidazole control acute infections?克氏锥虫:纳米囊包苯硝唑的摄入是否能控制急性感染?
Exp Parasitol. 2023 Jun;249:108520. doi: 10.1016/j.exppara.2023.108520. Epub 2023 Mar 29.
3
Levels and trends in Chagas disease-related mortality in Brazil, 2000-2019.2000-2019 年巴西克氏锥虫病相关死亡率的水平和趋势。
Acta Trop. 2021 Aug;220:105948. doi: 10.1016/j.actatropica.2021.105948. Epub 2021 May 7.
4
Resveratrol impacts in oxidative stress in liver during Trypanosoma cruzi infection.白藜芦醇对感染克氏锥虫时肝脏氧化应激的影响。
Microb Pathog. 2021 Apr;153:104800. doi: 10.1016/j.micpath.2021.104800. Epub 2021 Feb 18.
5
Human acute Chagas disease: changes in factor VII, activated protein C and hepatic enzymes from patients of oral outbreaks in Pará State (Brazilian Amazon).人类急性恰加斯病:巴西亚马逊州(巴西亚马逊地区)口腔爆发患者的凝血因子 VII、活化蛋白 C 和肝酶变化。
Mem Inst Oswaldo Cruz. 2020 Feb 27;115:e190364. doi: 10.1590/0074-02760190364. eCollection 2020.
6
Advances in nanocarriers as drug delivery systems in Chagas disease.纳米载体作为恰加斯病药物传递系统的研究进展。
Int J Nanomedicine. 2019 Aug 9;14:6407-6424. doi: 10.2147/IJN.S206109. eCollection 2019.
7
An evaluation of benznidazole as a Chagas disease therapeutic.评价苯硝唑作为一种治疗恰加斯病的药物。
Expert Opin Pharmacother. 2019 Oct;20(15):1797-1807. doi: 10.1080/14656566.2019.1650915. Epub 2019 Aug 28.
8
Tissue tropism in parasitic diseases.寄生虫病的组织嗜性。
Open Biol. 2019 May 31;9(5):190036. doi: 10.1098/rsob.190036.
9
Effects of resveratrol on the differentiation fate of neural progenitor cells of mouse embryos infected with Trypanosoma cruzi.白藜芦醇对感染克氏锥虫的小鼠胚胎神经祖细胞分化命运的影响。
Microb Pathog. 2019 Jul;132:156-161. doi: 10.1016/j.micpath.2019.04.040. Epub 2019 Apr 25.
10
Cytokine modulation, oxidative stress and thymic dysfunctions: Role of age-related changes in the experimental Trypanosoma cruzi infection: Age-related thymic dysfunctions and Trypanosoma cruzi infection.细胞因子调节、氧化应激和胸腺功能障碍:衰老相关变化在实验性克氏锥虫感染中的作用:衰老相关的胸腺功能障碍和克氏锥虫感染。
Cytokine. 2018 Nov;111:88-96. doi: 10.1016/j.cyto.2018.08.004. Epub 2018 Aug 18.